Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, Part II

Molecules

Volumn 19, Issue 10, 2014, Pages 15411-15439

  Foucourt, Alicia ^a   Hédou, Damien ^a   Dubouilh Benard, Carole ^a   Girard, Angélique ^b   Taverne, Thierry ^b   Casagrande, Anne Sophie ^b   Désiré, Laurent ^b   Leblond, Bertrand ^b   Besson, Thierry ^a  

^a NORMANDIE UNIVERSITÉ   (France)

^b Diaxonhit   (France)

Author keywords

Dimroth rearrangement; DYRK1A; DYRK1B; EHT 1610; EHT 3356; EHT 5372; EHT 6840; EHT 9851; Kinase inhibitors; Microwave assisted chemistry; Thiazolo 5,4 f quinazolines

Indexed keywords

DYRK KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYME ACTIVATION; HUMAN; METABOLISM; SYNTHESIS;

CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; QUINAZOLINES;

EID: 84907494556     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191015411     Document Type: Article

References (39)

1. Martin, L.; Latypova, X.; Wilson, C. M.; Magnaudeix, A.; Perrin, M.-L.; Terro, F. Tau protein kinases: Involvement in Alzheimer's disease. Ageing Res. Rev. 2013, 12, 289-309.
2. Flajolet, M.; He, G.; Heiman, M.; Lin, A.; Nairn, A. C.; Greengard, P. Regulation of Alzheimer's disease amyloid-β formation by casein kinase I. Proc. Nat. Acad. Sci. USA 2007, 104, 4159-4164.
3. Weinmann, H.; Metternich, R. Drug discovery process for kinase Inhibitors. ChemBioChem 2005, 6, 455-459;
4. this paper is the editorial of a special issue "Kinases in Drug Discovery" Chem BioChem 2005, 6, 453-574.
5. Loidreau, Y.; Marchand, P.; Dubouilh-Benard, C.; Nourrisson, M.-R.; Duflos, M.; Loaëc, N.; Meijer, L.; Besson, T. Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3, 2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3, 2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. Eur. J. Med. Chem. 2013, 59, 283-295.
6. Loidreau, Y.; Marchand, P.; Dubouilh-Benard, C.; Nourrisson, M.-R.; Duflos, M.; Lozach, O.; Loaëc, N.; Meijer, L.; Besson, T. Synthesis and biological evaluation of N-arylbenzo[b]thieno[3, 2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. Eur. J. Med. Chem. 2012, 58, 171-183.
7. Foucourt, A.; Dubouilh-Benard, C.; Chosson, E.; Corbière, C.; Buquet, C.; Iannelli, M.; Leblond, B.; Marsais, F.; Besson, T. Microwave-accelerated Dimroth rearrangement for the synthesis of 4-anilino-6-nitroquinazolines. Application to an efficient synthesis of a microtubule destabilizing agent. Tetrahedron 2010, 66, 4495-4502.
8. Logé, C.; Testard, A.; Thiéry, V.; Lozach, O.; Blairvacq, M.; Robert, J.-M.; Meijer, L.; Besson, T. Novel 9-oxo-thiazolo[5, 4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. Eur. J. Med. Chem. 2008, 43, 1469-1477.
9. Testard, A.; Logé, C.; Léger, B.; Robert, J.-M.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiéry, V.; Besson, T. Thiazolo[5, 4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2006, 16, 3419-3423.
10. Foucourt, A.; Hédou, D.; Dubouihl-Benard, C.; Désiré, L.; Casagrande, A.-S.; Leblond, B.; Loaëc, N.; Meijer, L.; Besson, T. Design and synthesis of thiazolo[5, 4-f]quinazolines as DYRK1A inhibitors, Part I. Molecules 2014, in press.
11. For a complete review see: Harris, C. S.; Hennequin, L. Morgentin, R.; Pasquet, G. Synthesis and functionnalization of 4-substituted quinazolines as kinases templates. In Targets in Heterocyclic Systems-Chemistry and Properties; Attanasi, O. A., Spinelli, D., Eds.; Italian Society of Chemistry: Roma, Italy, 2010; Volume 14, pp. 315-350.
12. Alexandre, F. R.; Domon, L.; Frère, S.; Testard, A.; Thiéry, V.; Besson, T. Microwaves in drug discovery and multi-step synthesis. Mol. Divers. 2003, 7, 273-280.
13. Alexandre, F. R.; Berecibar, A.; Wrigglesworth, R.; Besson, T. Efficient synthesis of thiazoloquinazolinone derivatives. Tetrahedron Lett. 2003, 44, 4455-4458.
14. Besson, T.; Guillard, J.; Rees, C. W. Multistep synthesis of thiazoloquinazolines under microwave irradiation in solution. Tetrahedron Lett. 2000, 41, 1027-1030.
15. Guillon, R.; Pagniez, F.; Picot, C.; Hédou, D.; Tonnerre, A.; Chosson, E.; Duflos, M.; Besson, T.; Logé, C.; Le Pape, P. Discovery of a novel broad-spectrum antifungal agent, derived from Albaconazole. ACS Med. Chem. Lett. 2013, 4, 288-292.
16. For recent example of this strategy for the synthesis of bioactive molecules see: Hédou, D.; Deau, E.; Dubouilh-Benard, C.; Sanselme, M.; Martinet, A.; Chosson, E.; Levacher, V.; Besson, T. Microwave-assisted (3+2) cycloaddition and Suzuki-Miyaura cross-coupling for a concise access to novel polyaromatic scaffolds. Eur. J. Org. Chem. 2013, 2013, 7533-7545.
17. Loidreau, Y.; Melissen, S.; Levacher, V.; Logé, C.; Graton, J.; Le Questel, J. Y.; Besson, T. Study of N1-alkylation of indoles from the reaction of 2 (or 3)-aminoindole-3-(or 2) carbonitriles with DMF-dialkylacetals. Org. Biomol. Chem. 2012, 20, 4916-4925.
18. Smith, B.; Medda, F.; Gokhale, V.; Dunckley, T.; Hulme, C. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: A new avenue for a disease modifying treatment of Alzheimer's? ACS Chem. Neurosci. 2012, 3, 857-872.
19. Frost, D.; Meechoovet, B.; Wang, T.; Gately, S.; Giorgetti, M.; Shcherbakova, I.; Dunckley, T. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS One 2011, 6, e19264.
20. Leder, S.; Weber, Y.; Altafaj, X.; Estivill, X.; Joost, H. G.; Becker, W. Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. Biochem. Biophys. Res. Commun. 1999, 254, 474-479.
21. Becker, W.; Soppa, U.; Tejedor, F. J. DYRK1A: A dotential Drug target for multiple Down Syndrome neuropathologies. CNS Neurol. Disord. Drug Targets 2014, 13, 26-33.
22. Patel, K.; Gadewar, M.; Tripathi, R.; Prasad, S. K.; Patel, D. K. A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid "Harmine". Asian Pac. J. Trop. Biomed. 2012, 2, 660-664.
23. Frederick, R.; Bruyere, C.; Vancraeynest, C.; Reniers, J.; Meinguet, C.; Pochet, L.; Backlund, A.; Masereel, B.; Kiss, R.; Wouters, J. Novel trisubstituted harmine derivatives with original in vitro anticancer activity. J. Med. Chem. 2012, 55, 6489-6501.
24. Muraki, M.; Ohkawara, B.; Hosoya, T.; Onogi, H.; Koizumi, J.; Koizumi, T.; Sumi, K. Yomoda, J.; Murray, M. V.; Kimura, H.; et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem. 2004, 27, 24246-24254.
25. Rosenthal, A. S.; Tanega, C.; Shen, M.; Mott, B. T.; Bougie, J. M.; Nguyen, D.-T.; Misteli, T.; Auld, D. S.; Maloney, D. J.; Thomas, C. J. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg. Med. Chem. Lett. 2011, 21, 3152-3158.
26. Debdab, M.; Carreaux, F.; Renault, S.; Soundararajan, M.; Fedorov, O.; Filippakopoulos, P.; Lozach, O.; Babault, L.; Tahtouh, T.; Baratte, B.; et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. Modulation of alternative pre-RNA splicing. J. Med. Chem. 2011, 54, 4172-4186.
27. Tahtouh, T.; Elkins, J. M.; Filippakopoulos, P.; Soundararajan, M.; Burgy, G.; Durieu, E.; Cochet, C.; Schmid, R. S.; Lo, D. C.; Delhommel, F.; et al. Selectivity, co-crystal structures and neuroprotective properties of Leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid Leucettamine B. J. Med. Chem. 2012, 55, 9312-9330.
28. Leblond, B.; Casagrande, A.-S.; Désiré, L.; Foucourt, A.; Besson, T. DYRK1 Inhibitors and Uses Thereof. WO 2013026806, 28 September 2013.
29. For a review of patent application WO 2013026806 see: Rosse, G. Pyrimidines as inhibitors of DYRK1A/DYRK1B as potential treatment for Down's Syndrome or Alzheimer's Disease. ACS Med. Chem Lett. 2013, 4, 502-503.
30. Casagrande, A.-S.; Bachelot, F.; Coutadeur, S.; Leblond, B.; Besson, T.; Pando, M. P.; Désiré, L. Structure activity relationship of a novel chemical class of Dyrk inhibitors. Cancer Res. 2013, 73, Abstract 2165.
31. Coutadeur, S.; Benyamine, H.; Delalonde, L.; De Oliveira, C.; Leblond, B.; Besson, T.; Casagrande, A.-S.; Taverne, T.; Girard, A.; Pando, M. P.; et al. A novel DYRK1A inhibitor for the treatment of Alzheimer's disease: Effect on Tau and amyloid pathologies in vitro. J. Neurochem. 2014, submitted.
32. Malinge, S.; Bliss-Moreau, M.; Kirsammer, G.; Diebol, L.; Chlon, T.; Gurbuxani, S.; Crispino, J. D. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down Syndrome. J. Clin. Investig. 2012, 122, 948-962.
33. Thompson, B. J.; Diebold, L.; Malinge, S.; Leblond, B.; Casagrande, A.-S.; Désiré, L.; Foucourt, A.; Besson, T.; Hijiya, N.; Crispino, J. D. The chromosome 21 kinase DYRK1A controls cell cycle exit and survival during lymphoid development and is a novel therapeutic target in acute lymphoblastic leukemia. Blood 2013, 122, 814.
34. Friedman, E. Mirk/Dyrk1B in cancer. J. Cell. Biochem. 2007, 102, 274-279.
35. Friedman, E. Mirk/Dyrk1B kinase in ovarian cancer. Int. J. Mol. Sci. 2013, 14, 5560-5575.
36. Deng, X.; Hu, J.; Ewton, D. Z.; Friedman, E. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR. Carcinogenesis 2014, 35, 1968-1976.
37. Deng, X.; Mercer, S. E.; Sun, C. Y.; Friedman, E. The normal function of the cancer kinase Mirk/dyrk1B is to reduce reactive oxygen species. Genes Cancer 2014, 5, 22-30.
38. Deng, X.; Hu, J.; Cunningham, M. J.; Friedman, E. Mirk kinase inhibition targets ovarian cancer ascites. Genes Cancer 2014, 5, 201-211.
39. Reaction Biology Corp. Available online: www.reactionbiology.com (accessed on 22 September 2014)